NYSE:CMO Capstead Mortgage (CMO) Stock Price, News & Analysis → Jim Cramer’s “The Biggest Drug Ever” (From Behind the Markets) (Ad) Free CMO Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$6.25▼$6.5450-Day Range$6.34▼$6.9652-Week Range$5.06▼$7.00Volume8.32 million shsAverage Volume891,322 shsMarket Capitalization$629.69 millionP/E Ratio9.29Dividend Yield0.92%Price TargetN/A Stock AnalysisStock Analysis Get Capstead Mortgage alerts: Email Address Ad Behind the MarketsJim Cramer’s “The Biggest Drug Ever”This firm's breakthrough has drawn investments from the biggest names in Big Pharma - With companies like Biogen, Sanofi, and Genentech pouring over $1 billion into it.Unlock the details of this groundbreaking opportunity here... About Capstead Mortgage Stock (NYSE:CMO)Capstead Mortgage Corp. operates as a self-managed real estate investment trust. It invests in a leveraged portfolio of residential mortgage pass-through securities consisting of adjustable-rate mortgage securities issued and guaranteed by government-sponsored enterprises, or by an agency of the federal government. The company was founded in 1985 and is headquartered in Dallas, TX.Read More Ad Behind the MarketsJim Cramer’s “The Biggest Drug Ever”This firm's breakthrough has drawn investments from the biggest names in Big Pharma - With companies like Biogen, Sanofi, and Genentech pouring over $1 billion into it.Unlock the details of this groundbreaking opportunity here... CMO Stock News HeadlinesFebruary 11, 2024 | investopedia.com7 Reasons Not to Refinance Your MortgageDecember 22, 2023 | businessinsider.comMortgage prepayment penalty: How it works and how much it costsApril 26, 2024 | Behind the Markets (Ad)Jim Cramer’s “The Biggest Drug Ever”This firm's breakthrough has drawn investments from the biggest names in Big Pharma - With companies like Biogen, Sanofi, and Genentech pouring over $1 billion into it.December 20, 2023 | thestreet.comCapstead Mortgage Corporation Pfd Ser EOctober 24, 2023 | investopedia.comBest 10-Year Mortgage RatesSeptember 29, 2023 | markets.businessinsider.comThe delayed effect of mortgage rates means housing affordability is actually about to get worseSeptember 29, 2023 | businessinsider.comBest Mortgage Refinance Lenders of October 2023September 14, 2023 | businessinsider.comMovement Mortgage Review 2023April 26, 2024 | Behind the Markets (Ad)Jim Cramer’s “The Biggest Drug Ever”This firm's breakthrough has drawn investments from the biggest names in Big Pharma - With companies like Biogen, Sanofi, and Genentech pouring over $1 billion into it.July 28, 2023 | investopedia.comHow Your Mortgage Affects Your Credit ScoreJune 24, 2023 | sfgate.comWhy a 15-year mortgage might be your best bet right nowMay 31, 2023 | investopedia.comMortgage Amortization CalculatorMay 3, 2023 | finance.yahoo.comWhat happens to your mortgage when you die?May 2, 2023 | cnbc.comRefinancing your mortgage could save you thousands — here are some of the best refinance lendersMay 2, 2023 | benzinga.comBest Online Mortgage LendersApril 27, 2023 | investopedia.com3-2-1 Buydown MortgageApril 19, 2023 | sfgate.comMortgage rates remain volatile: Compare the best ones hereApril 3, 2023 | thestreet.comCapstead Stock To Go Ex-dividend Tomorrow (CMO)April 3, 2023 | money.usnews.comComplete Checklist of Documents Needed for a MortgageFebruary 23, 2023 | seekingalpha.comFBRT.PE Franklin BSP Realty Trust, Inc. PFD SER EFebruary 9, 2023 | businessinsider.comThe average mortgage interest rate by state, credit score, year, and loan typeJanuary 29, 2023 | businessinsider.comWyndham Capital Mortgage Review 2023January 18, 2023 | money.usnews.com2023 Mortgage Forecast: Rates Expected to DeclineDecember 31, 2022 | forbes.comToday’s 15-Year Mortgage RatesDecember 30, 2022 | wsj.comMortgage Rates Record Biggest Calendar-Year Increase in 2022December 22, 2022 | forbes.comCurrent 30-Year Mortgage Rates: Compare Today’s RatesNovember 30, 2022 | wsj.comStarwood-Backed Reverse Mortgage Originator Files for BankruptcySee More Headlines Receive CMO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Capstead Mortgage and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings7/28/2021Today4/26/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorFinance Industry Real Estate Investment Trusts Sub-IndustryMortgage REITs Current SymbolNYSE:CMO CUSIP14067E50 CIK766701 Webwww.capstead.com Phone(214) 874-2323FaxN/AEmployees15Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)$0.65 Trailing P/E Ratio9.29 Forward P/E Ratio11.40 P/E GrowthN/ANet Income$-129,570,000.00 Net Margins74.89% Pretax MarginN/A Return on Equity10.89% Return on Assets0.86% Debt Debt-to-Equity Ratio11.11 Current Ratio21.42 Quick Ratio21.43 Sales & Book Value Annual Sales$186.74 million Price / Sales3.37 Cash Flow$1.60 per share Price / Cash Flow4.07 Book Value$6.83 per share Price / Book0.95Miscellaneous Outstanding Shares96,876,000Free FloatN/AMarket Cap$629.69 million OptionableOptionable Beta1.55 Social Links 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesPhillip A. ReinschPresident, CEO, Director & Executive VPLance J. PhillipsChief Financial Officer, Secretary & Senior VPRobert R. SpearsChief Investment Officer & Executive VPRoy S. KimTreasurer & Senior Vice PresidentLindsey CrabbeInvestor Relations OfficerKey CompetitorsNew York Mortgage TrustNASDAQ:NYMTDynex CapitalNYSE:DXRedwood TrustNYSE:RWTAres Commercial Real EstateNYSE:ACREARMOUR Residential REITNYSE:ARRView All Competitors CMO Stock Analysis - Frequently Asked Questions How were Capstead Mortgage's earnings last quarter? Capstead Mortgage Co. (NYSE:CMO) announced its quarterly earnings data on Wednesday, July, 28th. The real estate investment trust reported $0.09 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.14 by $0.05. Capstead Mortgage had a net margin of 74.89% and a trailing twelve-month return on equity of 10.89%. Is Capstead Mortgage a good dividend stock? Capstead Mortgage (NYSE:CMO) pays an annual dividend of $0.06 per share and currently has a dividend yield of 0.92%. The dividend payout ratio is 9.23%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, CMO will have a dividend payout ratio of 9.52% next year. This indicates that the company will be able to sustain or increase its dividend. Read our dividend analysis for CMO. What other stocks do shareholders of Capstead Mortgage own? Based on aggregate information from My MarketBeat watchlists, some companies that other Capstead Mortgage investors own include AGNC Investment (AGNC), Energy Transfer (ET), Two Harbors Investment (TWO), Annaly Capital Management (NLY), C3.ai (AI), Ford Motor (F), New Residential Investment (NRZ), SandRidge Permian Trust (PER), CBL & Associates Properties (CBL) and Invesco Mortgage Capital (IVR). This page (NYSE:CMO) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsFed launches fourth dollar overhaulStansberry ResearchBiden out June 13; Kamala won’t replace him?Paradigm PressThe only accurate crypto trading system I know …Weiss RatingsThe AI stock to buy right nowStockEarnings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Capstead Mortgage Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
